The German medicinal drug market is currently experiencing exceptional circumstances due to the global COVID-19 pandemic. Supply chain disruptions around the world have affected pharmaceutical imports to Germany, including medical cannabis imports. For example, many Canadian products are currently severely backordered. DEMECAN – the German specialist for medicinal cannabis – helps by importing medicinal cannabis from Bedrocan from the Netherlands to ensure a consistent supply for German pharmacies.
Even prior to the pandemic, in 2019 there were increasing cannabis supply shortages in Germany. The pandemic has encouraged DEMECAN to close supply gaps locally. To that end, last year the Federal Institute for Drugs and Medical Devices (BfArM) awarded DEMECAN a contract to produce and process medicinal cannabis for Germany. DEMECAN is currently constructing the manufacturing facility near Dresden. In addition, the DEMECAN wholesale department started the import of medicinal cannabis and is expanding its distribution network.
Dr. Cornelius Maurer, Co-founder and Managing Director of DEMECAN explains: “The current restrictions concerning the corona pandemic make it clear that Germany has to close supply chain gaps and provide its citizens with consistent access to medicinal cannabis. We are looking forward to cultivating our own medicinal cannabis in Germany soon and are glad to be able to provide Bedrocan cannabis to German pharmacies in the meantime. It is our goal to help patients in this hard time.”